-
公开(公告)号：US09499476B2
公开(公告)日：2016-11-22
申请号：US14692843
申请日：2015-04-22
Applicant: SUNOVION PHARMACEUTICALS INC.
Inventor： Craig R. Abolin , H. Scott Wilkinson , Paul McGlynn , William K. McVicar
IPC: C07C233/43 , A61K9/00 , A61K45/06 , A61K31/167 , C07C231/18 , A61K31/4015
CPC classification number: C07C233/43 , A61K9/0075 , A61K9/008 , A61K31/167 , A61K31/4015 , A61K45/06 , C07B2200/13 , C07C231/18
Abstract: The compound of formula (I) is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
-
公开(公告)号：US08889685B2
公开(公告)日：2014-11-18
申请号：US13928571
申请日：2013-06-27
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： H. Scott Wilkinson , Richard Hsia , Tushar Misra , Kostas Saranteas , Patrick Mousaw
IPC: A61K31/444 , A61K31/495 , A61K31/4985 , C07D213/61 , C07D295/182 , C07D471/04 , C07D487/04
CPC classification number: C07D487/04 , C07C57/145
Abstract: Maleate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided. The salts are useful for treating sleep disorders.
Abstract translation: （6-（5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4-b ]吡嗪）。 这些盐可用于治疗睡眠障碍。
-
公开(公告)号：US20140135300A1
公开(公告)日：2014-05-15
申请号：US14157793
申请日：2014-01-17
Applicant: SUNOVION PHARMACEUTICALS INC.
Inventor： Craig R. Abolin , H. Scott Wilkinson , Paul McGlynn , William K. McVicar
IPC: C07C233/43 , A61K31/4015 , A61K45/06 , A61K31/167
CPC classification number: C07C233/43 , A61K9/0075 , A61K9/008 , A61K31/167 , A61K31/4015 , A61K45/06 , C07B2200/13 , C07C231/18
Abstract: The compound of formula (I) is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
Abstract translation: 式（I）化合物是用作治疗与可逆性阻塞性气道疾病等相关的支气管收缩剂的支气管扩张剂的水稳定性长效β2-选择性肾上腺素受体激动剂。 公开了制备式（I）化合物以及相关中间体的方法。
-
公开(公告)号：US20130296607A1
公开(公告)日：2013-11-07
申请号：US13934996
申请日：2013-07-03
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： Craig R. Abolin , H. Scott Wilkinson , Paul McGlynn , William K. McVicar
IPC: C07C231/18
CPC classification number: C07C233/43 , A61K9/0075 , A61K9/008 , A61K31/167 , A61K31/4015 , A61K45/06 , C07B2200/13 , C07C231/18
Abstract: The compound of formula (I) is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
Abstract translation: 式（I）化合物是用作治疗与可逆性阻塞性气道疾病等相关的支气管收缩剂的支气管扩张剂的水稳定的长效β2-选择性肾上腺素受体激动剂。 公开了制备式（I）化合物以及相关中间体的方法。
-
Patent Agency Ranking
5.发明授权Method of decreasing the bitterness of a pharmaceutical dosage form containing zopiclone 有权降低含有佐匹克隆的药物剂型的苦味的方法公开(公告)号：US08889686B2
公开(公告)日：2014-11-18
申请号：US13932324
申请日：2013-07-01
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： H. Scott Wilkinson , Richard Hsia , Tushar Misra , Kostas Saranteas , Patrick Mousaw
IPC: A61K31/44 , A61K31/495 , A61K31/4985 , C07D213/61 , C07D295/182 , C07D471/04 , C07D487/04 , C07C59/245
CPC classification number: C07D487/04 , C07C59/245
Abstract: L malate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are disclosed for decreasing the bitterness of eszopiclone dosage forms
Abstract translation: （6-（5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰基氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4- b]吡嗪）用于降低右佐佐单抗剂型的苦味
-
6.发明授权Method for treating anxiety with a dosage form of besylate salts of zopiclone or eszopiclone 有权用佐匹克隆或替佐氟隆的苯磺酸盐剂型治疗焦虑症的方法公开(公告)号：US08809332B2
公开(公告)日：2014-08-19
申请号：US13927439
申请日：2013-06-26
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： Richard Hsia , H. Scott Wilkinson , Tushar Misra , Kostas Saranteas , Patrick Mousaw
IPC: A61K31/444 , A61K31/495 , A61K31/4985 , C07D213/61 , C07D295/182 , C07D471/04
CPC classification number: C07D487/04
Abstract: Besylate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided.
Abstract translation: -5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4-b ]吡嗪）。
-
公开(公告)号：US08664441B2
公开(公告)日：2014-03-04
申请号：US13934996
申请日：2013-07-03
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： Craig R. Abolin , H. Scott Wilkinson , Paul McGlynn , William K. McVicar
IPC: C07C233/05
CPC classification number: C07C233/43 , A61K9/0075 , A61K9/008 , A61K31/167 , A61K31/4015 , A61K45/06 , C07B2200/13 , C07C231/18
Abstract: The compound of formula (I) is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
Abstract translation: 式（I）化合物是用作治疗与可逆性阻塞性气道疾病等相关的支气管收缩剂的支气管扩张剂的水稳定的长效β2-选择性肾上腺素受体激动剂。 公开了制备式（I）化合物以及相关中间体的方法。
-
公开(公告)号：US09040588B2
公开(公告)日：2015-05-26
申请号：US14157793
申请日：2014-01-17
Applicant: SUNOVION PHARMACEUTICALS INC.
Inventor： Craig R. Abolin , H. Scott Wilkinson , Paul McGlynn , William K. McVicar
IPC: C07C233/43 , A61K31/167 , A61K31/4015 , A61K45/06 , C07C231/18
CPC classification number: C07C233/43 , A61K9/0075 , A61K9/008 , A61K31/167 , A61K31/4015 , A61K45/06 , C07B2200/13 , C07C231/18
Abstract: The compound of formula (I) is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
Abstract translation: 式（I）化合物是用作治疗与可逆性阻塞性气道疾病等相关的支气管收缩剂的支气管扩张剂的水稳定性长效β2-选择性肾上腺素受体激动剂。 公开了制备式（I）化合物以及相关中间体的方法。
-
9.发明申请Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders 审中-公开依佐匹克隆和反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基）-1,2,3， 4-四氢-1-萘胺，以及更年期和心情，焦虑和认知障碍的治疗方法公开(公告)号：US20140315910A1
公开(公告)日：2014-10-23
申请号：US14317754
申请日：2014-06-27
Applicant: SUNOVION PHARMACEUTICALS INC.
Inventor： Judy Caron , Thomas Wessel , Karim LALJI , Mark Varney , Roger P. Bakale , Surendra P. Singh , H. Scott Wilkinson , Xiping Su , Zhengxu Han , Stefan G. Koenig
IPC: A61K31/4985 , A61K31/135
CPC classification number: A61K31/4985 , A61K31/135 , C07C211/42 , C07C2602/10 , A61K2300/00
Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
Abstract translation: 本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，所述活性剂一起可以用于治疗例如更年期，情绪障碍，焦虑障碍或认知障碍。 药物组合物的第一组分是镇静剂佐佐匹克。 药物组合物的第二组分是反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基） 2,3,4-四氢-1-萘胺。 本发明还涉及治疗绝经，围绝经期，情绪障碍，焦虑障碍和认知障碍的方法。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.015 seconds)
